CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016)
CRISPR Therapeutics AG (CRSP) reported Preferred Stock Liabilities of $128.6 million for Q3 2016, up 322.58% sequentially from $30.4 million in Q4 2015.
CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 2 years of Preferred Stock Liabilities data on file, last reported at $128.6 million in Q3 2016.
- For the quarter ending Q3 2016, Preferred Stock Liabilities changed N/A year-over-year to $128.6 million; the trailing twelve-month figure through Sep 2016 stood at $128.6 million (changed N/A YoY), and the FY2015 full-year result was $30.4 million, up 496.75% from the prior year.
- Preferred Stock Liabilities rose to $128.6 million in Q3 2016, from $30.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $128.6 million in Q3 2016 to a low of $30.4 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 128.63 Mn |
| Dec 31, 2015 | 30.44 Mn |